Biogen has received a clutch of useful data from the initially disappointing SYNERGY trial, and is now evaluating the design of further possible Phase II clinical studies of opicinumab, a potential myelin repair agent for the treatment of multiple sclerosis.
ECTRIMS 2016: Biogen Makes Headway in MS Remyelination Studies
Biogen has identified the type of MS patient likely to respond to its remyelination approach with the investigational MAb opicinumab, even though its Phase II SYNERGY trial missed its primary endpoint.
More from R&D
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.
• By
Japanese incubator Ciconia has just started verifying its first drug candidate with a vision of building domestic startups with globally competitive assets.
• By
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
• By
Start-ups from China dominated the fastest-growing share prices for mid-cap biopharma companies in Q1, while the biggest decliners were mainly US firms.
More from Scrip
• By
Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.
• By
The agency loosened requirements for echocardiograms and removed contraindications for a number of commonly used drugs.
• By
The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.